Triple threat: new combo therapy targets advanced endometrial cancer

NCT ID NCT05819892

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether combining chemotherapy and radiation, followed by more chemotherapy plus the immunotherapy drug dostarlimab, is safe and tolerable for people with stage IIIC node-positive endometrial cancer. The study aims to see if this approach can help control the cancer after surgery. Only 21 participants will be enrolled, and the main focus is on side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (paclitaxel, carboplatin, cisplatin) plus radiation therapy and dostarlimab
What this could lead to: If successful, this could point toward a new treatment option that helps control advanced endometrial cancer after surgery.
What could go wrong: This is a very early Phase 1 trial with only 21 participants, so it is primarily testing safety, not effectiveness. The combination may cause significant side effects and may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.